ABBOTT LABORATORIES — Capital/Financing Update 2001

May 14, 2001

8-K/A 1 a2048098z8-ka.htm FORM 8-K/A Prepared by MERRILL CORPORATION QuickLinks -- Click here to rapidly navigate through this document

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K/A Amendment No. 1

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

March 2, 2001 Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in its charter)

User-specified TAGGED TABLE

Illinois	1-2189	36-0698440
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

end of user-specified TAGGED TABLE

100 Abbott Park Road Abbott Park, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (847) 937-6100

ZEQ.=1,SEQ=1,EFW="2048098",CP="ABBOTT LABORATORIES",DN="1",CHK=749233,FOLIO='blank',FILE='DISK012:[01CHI3.01CHI2973]BA2973A.;7',USER='MBLOUNT',CD='14-MAY-2001;12:23' Generated by Merrill Corporation (www.merrillcorp.com)

Abbott Laboratories ("Abbott") hereby files Amendment No. 1 to its Current Report on Form 8-K dated March 2, 2001, solely to file Exhibits 99.1 and 99.2.

Item 7. Financial Statements and Exhibits .

(a) The required financial statements in connection with Abbott's acquisition of BASF's pharmaceutical business are attached as Exhibit 99.1 and incorporated herein by this reference.

(b) The required pro forma financial information in connection with Abbott's acquisition of BASF's pharmaceutical business is attached as Exhibit 99.2 and incorporated herein by this reference.

(c) Exhibits.

User-specified TAGGED TABLE

Exhibit No.		Exhibit
2.1	(1)	Amendment to Purchase Agreement between BASF Aktiengesellschaft and Abbott Laboratories recorded on March 2, 2001, filed as Exhibit 2.1 to the Form 8-K dated March 2, 2001 and incorporated herein by this
reference.
2.2	(1)	Purchase Agreement between BASF Aktiengesellschaft and Abbott Laboratories recorded on December 14, 2000, filed as Exhibit 2.1 to the 2000 Abbott Laboratories Annual Report on Form 10-K and incorporated
herein by this reference.
2.3		Press Release, dated March 2, 2001, filed as Exhibit 2.3 to the Form 8-K dated March 2, 2001 and incorporated herein by this reference.
23.1		Consent of Deloitte & Touche GmbH
23.2		Consent of Ernst & Young
23.3		Consent of Asahi & Co.
99.1		Consolidated financial statements for BASF Pharmaceutical Business for the years ended December 31, 2000 and 1999.
99.2		Pro forma financial information—Abbott Laboratories and subsidiaries and the BASF Pharmaceutical Business.

end of user-specified TAGGED TABLE (1) Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment separately filed with the Securities and Exchange Commission. ZEQ.=1,SEQ=2,EFW="2048098",CP="ABBOTT LABORATORIES",DN="1",CHK=607709,FOLIO='blank',FILE='DISK012:[01CHI3.01CHI2973]DE2973A.;18',USER='MBLOUNT',CD='14-MAY-2001;14:20' Generated by Merrill Corporation (www.merrillcorp.com) TOC_END

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

User-specified TAGGED TABLE

ABBOTT LABORATORIES
By:	/s/ THOMAS C. FREYMAN Thomas C. Freyman Senior Vice President, Finance and Chief Financial Officer

end of user-specified TAGGED TABLE

Date: 5/14/01

ZEQ.=1,SEQ=3,EFW="2048098",CP="ABBOTT LABORATORIES",DN="1",CHK=46001,FOLIO='blank',FILE='DISK012:[01CHI3.01CHI2973]JC2973A.;8',USER='SLYUBOM',CD='14-MAY-2001;15:26' Generated by Merrill Corporation (www.merrillcorp.com) TOC_END

EXHIBIT INDEX

User-specified TAGGED TABLE

Exhibit No.		Exhibit
2.1	(1)	Amendment to Purchase Agreement between BASF Aktiengesellschaft and Abbott Laboratories recorded on March 2, 2001, filed as Exhibit 2.1 to the Form 8-K dated March 2, 2001 and incorporated herein by this
reference.
2.2	(1)	Purchase Agreement between BASF Aktiengesellschaft and Abbott Laboratories recorded on December 14, 2000, filed as Exhibit 2.1 to the 2000 Abbott Laboratories Annual Report on Form 10-K and incorporated
herein by this reference.
2.3		Press Release, dated March 2, 2001, filed as Exhibit 2.3 to the Form 8-K dated March 2, 2001 and incorporated herein by this reference.
23.1		Consent of Deloitte & Touche GmbH
23.2		Consent of Ernst & Young
23.3		Consent of Asahi & Co.
99.1		Consolidated financial statements for BASF Pharmaceutical Business for the years ended December 31, 2000 and 1999.
99.2		Pro forma financial information—Abbott Laboratories and subsidiaries and the BASF Pharmaceutical Business.

end of user-specified TAGGED TABLE (1) Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment separately filed with the Securities and Exchange Commission. ZEQ.=1,SEQ=4,EFW="2048098",CP="ABBOTT LABORATORIES",DN="1",CHK=87076,FOLIO='blank',FILE='DISK012:[01CHI3.01CHI2973]KA2973A.;15',USER='MBLOUNT',CD='14-MAY-2001;14:16' Generated by Merrill Corporation (www.merrillcorp.com)

QuickLinks

TOC_BEGIN SIGNATURE TOC_BEGIN EXHIBIT INDEX SEQ=,FILE='QUICKLINK',USER=JKANTOR,SEQ=,EFW="2048098",CP="ABBOTT LABORATORIES",DN="1" TOCEXISTFLAG